Humanigen, Inc.
from OTCQB Podcast Hosted by OTC Markets Group
Humanigen, Inc. (OTCQB: HGEN) is a biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization, and gene-knockout platforms. We welcome back Chairman & CEO of Humanigen, Cameron Durrant, MD, MBA, to explain the significance of "GM-CSF" pathway science for COVID-19 patients.
Embed this episode
No transcript yet.
Similar podcasts
Frequently asked questions
How long is this episode of OTCQB Podcast?
This episode is 11 minutes long.
When was this OTCQB Podcast episode published?
This episode was published on April 29, 2020.
Can I download this OTCQB Podcast episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.